How the diversified business model of Catalent, Inc (XNYS:CTLT) provides a safe investment opportunity?

How the diversified business model of Catalent, Inc (XNYS:CTLT) provides a safe investment opportunity?

ByMarketFacts

Catalent, Inc. (NYSE: CTLT) is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. Operating as a Contract Development and Manufacturing organization (CDMO), the company serves a wide range of customers in the pharmaceutical, biotech, and consumer health industries.
It operates under four main segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. The company is known for its expertise in developing and manufacturing complex and difficult-to-formulate products, and for its ability to rapidly scale up production to meet the needs of its customers.

Why this satellite communications stock should be on your radar: Globalstar, Inc (XNYS:GSAT)

Why this satellite communications stock should be on your radar: Globalstar, Inc (XNYS:GSAT)

ByMarketFacts

Globalstar, Inc. (XNYS: GSAT) is a provider of mobile satellite voice and data services. The company operates a low Earth orbit (LEO) satellite constellation, which it uses to provide communications services to customers in remote and hard-to-reach areas. Globalstar’s services include satellite voice and data communications, asset tracking, and remote sensing. The company’s products include satellite phones, modems, and tracking devices, as well as a range of airtime and service plans. Globalstar was founded in 1991 and is headquartered in Covington, Louisiana.

Is STEM a hallmark for clean energy solutions: Stem, Inc. (XNYS:STEM)?

Is STEM a hallmark for clean energy solutions: Stem, Inc. (XNYS:STEM)?

ByMarketFacts

Stem, Inc. (XNYS:STEM) provides clean energy solutions and services designed to maximize the economic, environmental, and resiliency value of energy assets and portfolios. It operates as a digitally connected and intelligent energy storage network provider in the United States and internationally. It offers energy storage systems sourced from original equipment manufacturers (OEMs).

The company also provides Athena, an artificial intelligence platform, which offers battery hardware and software-enabled services to operate the energy storage systems.

What makes Hannon Armstrong (XNYS:HASI) a textbook buy stock?

What makes Hannon Armstrong (XNYS:HASI) a textbook buy stock?

ByMarketFacts

Hannon Armstrong Sustainable Infrastructure Capital Inc (XNYS: HASI) finances the US energy markets using debt and equity. The company’s investments are divided into energy-efficiency initiatives and renewable-energy projects. Energy-efficiency initiatives lower the energy usage and expense of a building or facility by improving or installing building components such as heating, ventilation, and air conditioning systems, lighting, energy controls, roofs, windows, building shells, and heat and power systems. Renewable-energy projects use greener energy sources like solar and wind to create electricity. The organization also offers finance for other initiatives to improve energy efficiency and the environment. 

The 7-Days Twitter Makeover by Elon Musk

The 7-Days Twitter Makeover by Elon Musk

ByMarketFacts

Earlier this year, Elon Musk announced his decision to buy Twitter. Seven months of petty tweets, accusations, and court battles finally led to the world’s richest man closing on a purchase of the 15th most popular social networking site. Shareholders approved the sale of Twitter in September when Elon Musk purchased these shares for $54.20 per share.
From November 8th, Twitter will no longer trade on public markets and no longer be listed on the New York Stock Exchange. In essence, Musk benefits from Twitter’s status as a private company. Companies that are not publicly traded are not required to report quarterly financial results and are also easier to control and subject to fewer regulations.

Are Green Bonds good investment option for long term retail Investors?

Are Green Bonds good investment option for long term retail Investors?

ByMarketFacts

Green Bonds is a type of fixed income security issued to raise money for climate & environmental projects. Like any other type of bond, green bonds offer a stated return and represent a loan from an investor to a company, organization, or government agency.

Green bonds may come with tax incentives such as tax exemption and tax credits, making them a more attractive investment vs. a comparable taxable bond. Investors interested in green bonds should learn the diverse types and the pros and cons of investing before buying.

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

ByMarketFacts

Douglas Elliman Inc. (XYNS: DOUG) is a real estate company. Among other real estate-related services, it provides sales, rentals, and new development in combination with mortgages and title insurance. The company operates in two divisions: Real Estate Brokerage and Corporate and Other. The company makes revenue from Commission and other brokerage income from existing house sales, Commission and other brokerage income from development marketing, Property management income, and Title fees. 

Are Novavax’s protein technology Covid shots & omicron-fighting prototype worth Investing : Novavax, Inc. (NASDAQ: NVAX) ?

Are Novavax’s protein technology Covid shots & omicron-fighting prototype worth Investing : Novavax, Inc. (NASDAQ: NVAX) ?

ByMarketFacts

Novavax, Inc (NASDAQ: NVAX) is a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Prior to 2020, company developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases.